Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs RLX Technology Inc — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while RLX Technology Inc trades at $1.73 (market cap $2.10B). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 2.9× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.81% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and RLX Technology Inc for 35 Days on average.
| IOVA | RLX | |
|---|---|---|
Market Cap | $6.04B | $2.10B |
Volume | 14,805,993 | 1,079,706 |
Sector | Health | Consumer Staples |
52-Week High | $14.82 | $2.57 |
52-Week Low | $1.81 | $1.68 |
Typical Hold Time | 0 Days | 35 Days |
Enterprise Value | $5.97B | $832.26M |
Dividend Yield | — | 5.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RLX Technology trades at $1.72, down 0.58% and near its 52-week low, with a bearish technical signal from moving averages. Fundamentally, the company shows solid profitability with 21.87% net income margin and attractive valuation metrics including P/E of 15.46 and P/B of 0.91. Recent quarterly earnings have consistently missed expectations, though revenue growth remains positive with 2026 projections showing $4.5B revenue and $985M net income.
The stock presents a value opportunity given discounted valuation, but faces headwinds from earnings misses and bearish technicals. International expansion through European acquisitions provides growth catalysts, though execution risks and margin compression require monitoring. Analyst sentiment remains cautious with 100% hold rating, suggesting limited near-term upside potential despite fundamental strengths.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
